Repurposing Research to Improve Patient Outcomes in Huntington's Disease

Description / Background
This Request for Proposals is soliciting research proposals to identify repurposed treatments for Huntington's disease. We are interested in generic or proprietary drugs, devices and nutraceuticals that could be repurposed to reduce the symptoms, progression and/or incidence of Huntington's disease, to thereby improve patient outcomes and reduce the suffering caused by this disease. Repurposed therapies may be used alone or in combination with other therapies. Therapies must already have FDA approval or other availability for human use.

Our strongest interest is in projects that are ready for a proof of concept clinical trial supported by strong preclinical scientific evidence or clinical observations. We are also open to late stage preclinical work that would directly lead to repurposing clinical trials.

Diseases/Conditions

Huntington's disease

Treatments

Any repurposed drugs, devices or nutraceuticals

Project Type

- Human Clinical Trial
- Animal Trial

Timeline

Project Must Start by: 11-01-2018

Project Must Finish by: 12-01-2021

Do you have a preference for where the research should take place?
This RFP is open to all academic research institutions in the United States and Canada. Researchers with collaborators in the United States or Canada are also encouraged to apply.

Do you have a preference for where you would like to see patient impact?
Huntington's disease

Restrictions
There are no other restrictions other than those described above.

Other Information for Researchers
Cost effectiveness, speed and patient impact are key ranking criteria for a successful Letter of Intent (LOI). LOIs will undergo a scientific review, with a subset selected for Full Grant submissions. The maximum total budget allowed is $100,000. Projects of $50,000 or less are preferred, but we will accept all projects up to $100,000. The Cures Within Reach/CureAccelerator co-funding model requires that the research institution provide 20% co-funding of the submitted total budget for all funded repurposing research projects.

Funding Available
Minimum $25,000
Maximum $100,000

Funding Description
The Cures Within Reach/CureAccelerator co-funding model requires that the research institution provide 20% co-funding of the submitted total budget for all funded repurposing research projects.
Open to co-funding

Co-Funding Description
We will accept projects that already have funding from another source and require additional funding.

Due Date for Project Proposal Summary Submissions